v3.26.3
Segments - Schedule of Drug Development Segment and Reconciliation to Consolidated Net Loss Segment Operations (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Revenue $ 0 $ 334 $ 235 $ 1,955
Clinical expense 3,415 1,729 7,450 5,943
Preclinical expense 573 1,131 1,005 3,097
Chemistry, manufacturing, and controls 373 792 1,067 3,065
IPR&D expense 6,199 5,452 22,441 17,735
Selling, general and administrative 3,562 3,287 12,268 10,815
Interest expense 0 0 0 173
Interest income (617) (454) (1,786) (1,759)
Other segment expense (income) [1] 1,152 2,440 (5,409) 1,488
Segment net loss (8,458) (8,591) (22,360) (20,867)
Adjustments and reconciling items 0 0 0 0
Net loss (8,458) (8,591) (22,360) (20,867)
In process research and development        
Segment Reporting [Line Items]        
IPR&D expense $ 0 $ 0 $ 8,000 $ 0
[1] Other segment expense (income) includes other research and development expense, amortization of debt issuance costs and discount, other income, and the warrant liabilities fair value adjustment.